CTI Plans Label Expansion For Zevalin After Acquiring The NHL Drug From Biogen
This article was originally published in Pharmaceutical Approvals Monthly
Cell Therapeutics plans to initiate two clinical trials evaluating the use of the non-Hodgkin's B-cell lymphoma drug Zevalin (ibritumomab tiuxetan) in front-line lymphoma settings to drive revenues of the product after acquiring it from Biogen Idec. The company announced plans to buy Zevalin for $30 million in up-front and milestone payments Aug. 16
You may also be interested in...
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.